The advantages of combination therapy on hypertension: development of immediate release perindopril–indapamide tablet and assessment of bioequivalence studies.

Hypertension has a major associated risk for organ damage and mortality, which is further heightened in patients with prior cardiovascular events, comorbid diabetes mellitus, microalbuminuria and renal impairment. Convers Plus tablet including perindopril erbumine (PE), which is an angiotensin converting enzyme (ACE) inhibitor, and indapamide, which is diuretic, was designed as a combined tablet to succes in the treatment of hypertension. Physico-pharmaceutical properties and characterization studies were evaluatedin vitroconditions. Later onin vivostudy was planned as a cross-designed, randomized, open-labeled, single-dose, single-center studyviaperoral route in 24 healthy male subjects. In this study, bioequivalence with primary pharmacokinetical target parameters reference (Bipreterax 4/1.25 mg Tablet-S.A.Servier Benelux N.V.) and test (Convers Plus 4/1.25 mg Tablet-ARGESAN Pharmaceutical Company) tablets have been found bioequivalent. The results of pharmacokinetic parameters for perindopril, perindoprilat and indapamide were found asCmax = 23.179 µg/mL,tmax = 0.729 h,t1/2 = 1.429 h; AUC0–t = 26.998 µgs/mL, AUC0–inf = 27.117 µgs/mL;Cmax = 1.834 µg/mL,tmax = 8.792 h,t1/2 = 40.699 h; AUC0–t = 54.828 µgs/mL, AUC0–inf = 77.113 µgs/mL;Cmax = 18.994 µg/mL,tmax = 3.417 h,t1/2 = 16.626 h and AUC0–t = 385.829 µgs/mL, AUC0–inf = 410.728 µgs/mL respectively. In conclusion, physico-pharmaceutical properties and results of clinical trials show that Convers Plus tablets have been found as bioequivalent for perindopril, perindoprilat and indapamide in terms of AUC andCmax, in 90% confidence limits. [ABSTRACT FROM AUTHOR]

Copyright of Pharmaceutical Development & Technology is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)